{"entity":{"id":"cic","kind":"target","name":"CIC","aka":["capicua transcriptional repressor","Protein capicua homolog","KIAA0306"],"tldr":"CIC (Protein capicua homolog) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 4 more.","summary":"Transcriptional repressor which plays a role in development of the central nervous system (CNS). In concert with ATXN1 and ATXN1L, involved in brain development.\n\nCIViC holds 11 clinical evidence items and 0 assertions across 3 variants, naming Trametinib, Vemurafenib and Selumetinib. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.76, genetic association 0.00, somatic mutation 0.85). IntOGen calls it a driver in 4 cohorts (1 activating, 3 loss-of-function), covering Hepatocellular Carcinoma, Low-Grade Glioma, NOS, Lung Adenocarcinoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:14214","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14214"},{"label":"UniProt Q96RK0","url":"https://www.uniprot.org/uniprotkb/Q96RK0/entry"},{"label":"NCBI Gene 23152","url":"https://www.ncbi.nlm.nih.gov/gene/23152"},{"label":"Ensembl ENSG00000079432","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000079432"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["colorectal","lung-cancer","pancreatic","hcc","skin-cancer","melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05491525"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 11 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Low-Grade Glioma, NOS."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CIC","role":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:14214","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14214","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q96RK0","url":"https://www.uniprot.org/uniprotkb/Q96RK0/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CIC","url":"https://civicdb.org/features/9326","note":"11 evidence items, 0 assertions, 3 variants; diseases: Lung Cancer, Melanoma, Colon Cancer, Pancreatic Cancer (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000079432","url":"https://platform.opentargets.org/target/ENSG00000079432/associations","note":"association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: colorectal cancer 0.54, melanoma 0.55, skin cancer 0.56 (GraphQL API, CC0)"},{"label":"IntOGen CIC","url":"https://www.intogen.org/search?gene=CIC","note":"driver in 4 cohorts (Act 1, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"specificity":"tumour-specific","distribution":"many-types","specificityNote":"Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CIC: RNA low tissue specificity; high antibody staining in 2 normal tissues; highest cancer staining breast cancer (8 of 10 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Lung cancer (all types), Pancreatic ductal adenocarcinoma, Hepatocellular carcinoma, Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"UniProt Q96RK0","url":"https://www.uniprot.org/uniprotkb/Q96RK0/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CIC","url":"https://civicdb.org/features/9326","note":"11 evidence items, 0 assertions, 3 variants; diseases: Lung Cancer, Melanoma, Colon Cancer, Pancreatic Cancer (GraphQL API, CC0)"},{"label":"IntOGen CIC","url":"https://www.intogen.org/search?gene=CIC","note":"driver in 4 cohorts (Act 1, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"},{"label":"Human Protein Atlas CIC tissue","url":"https://www.proteinatlas.org/ENSG00000079432-CIC/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000079432 associations","url":"https://platform.opentargets.org/target/ENSG00000079432/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:14214","ensembl":"ENSG00000079432","uniprot":"Q96RK0","entrez":"23152","firstDescribed":1997,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 1997, \"Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/9205841/","biology":"Transcriptional repressor which plays a role in development of the central nervous system (CNS). In concert with ATXN1 and ATXN1L, involved in brain development. Location: Nucleus (UniProt). Locus 19q13.2 (HGNC).","whereFound":["Colorectal cancer: Open Targets association 0.54 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease","Lung cancer: CIViC evidence names this disease","Pancreatic ductal adenocarcinoma: CIViC evidence names this disease","Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)","Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)","Melanoma: Open Targets association 0.55 with melanoma (MONDO_0005105); CIViC evidence names this disease"],"targetClass":"transcription","prevalence":[]},"route":"/targets/cic/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"trial":[{"id":"nct05491525","kind":"trial","name":"Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC","route":"/trials/nct05491525/"}]}}